Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non Clear Cell Renal Cell Carcinoma”

393 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 393 results

Early research (Phase 1)Study completedNCT00056537
What this trial is testing

ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer

Who this might be right for
Non-Small-Cell Lung CarcinomaRenal Cell CarcinomaPancreatic Cancer
Active Biotech AB 44
Testing effectiveness (Phase 2)Study completedNCT00101348
What this trial is testing

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

Who this might be right for
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Basal Cell Carcinoma of the Lip+64 more
National Cancer Institute (NCI) 66
Testing effectiveness (Phase 2)Study completedNCT03511391
What this trial is testing

CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors

Who this might be right for
Urothelial CarcinomaMelanomaRenal Cell Carcinoma+2 more
University Hospital, Ghent 99
Not applicableStudy completedNCT03744585
What this trial is testing

Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts.

Who this might be right for
Renal Cell Carcinoma
Ipsen 450
Early research (Phase 1)Active Not RecruitingNCT05891171
What this trial is testing

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Who this might be right for
Advanced CancerAdvanced MalignanciesBladder Cancer+9 more
Arcus Biosciences, Inc. 40
Testing effectiveness (Phase 2)Ended earlyNCT02771626
What this trial is testing

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Clear Cell Renal Cell Carcinoma (ccRCC)MelanomaNon-small Cell Lung Cancer (NSCLC)
Calithera Biosciences, Inc 118
Early research (Phase 1)Study completedNCT02835833
What this trial is testing

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

Who this might be right for
Renal Cell CarcinomaColorectal AdenocarcinomaNon-squamous Non-small Cell Lung Cancer+2 more
University of Alabama at Birmingham 21
Early research (Phase 1)Active Not RecruitingNCT05653882
What this trial is testing

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

Who this might be right for
Solid TumorNon Small Cell Lung CancerMelanoma+2 more
Asher Biotherapeutics, Inc. 552
Not applicableStudy completedNCT04006405
What this trial is testing

AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC

Who this might be right for
Clear Cell Renal Cell Carcinoma
Elypta 280
Testing effectiveness (Phase 2)Study completedNCT00688753
What this trial is testing

RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe

Who this might be right for
CarcinomaRenal CellNon Clear Cell Renal Carcinoma+2 more
Novartis Pharmaceuticals 92
Not applicableAvailableNCT06090331
What this trial is testing

89Zr-DFO-girentuximab Expanded Access Program (EAP)

Who this might be right for
Clear Cell Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
Not applicableActive Not RecruitingNCT06630429
What this trial is testing

A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors

Who this might be right for
Non-Small Cell Lung CancerRenal Cell Carcinoma (RCC)
Ohio State University Comprehensive Cancer Center 100
Early research (Phase 1)Study completedNCT02219711
What this trial is testing

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

Who this might be right for
Advanced Cancer
Mirati Therapeutics Inc. 193
Testing effectiveness (Phase 2)UnknownNCT03177239
What this trial is testing

Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)

Who this might be right for
Renal Cell CarcinomaPapillary Renal Cell Carcinoma Type 1Papillary Renal Cell Carcinoma Type 2+3 more
Australian and New Zealand Urogenital and Prostate Cancer Trials Group 85
Large-scale testing (Phase 3)Study completedNCT00492986
What this trial is testing

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

Who this might be right for
Carcinoma, Renal Cell
Bayer 1,150
Not applicableStudy completedNCT00460798
What this trial is testing

SUTENT® In The First Line Treatment Of Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
Pfizer 356
Testing effectiveness (Phase 2)Study completedNCT01538238
What this trial is testing

Pazopanib_NCRCC,Ph2 STUDY

Who this might be right for
Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma
Samsung Medical Center 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT03647163
What this trial is testing

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Who this might be right for
Solid TumorNon Small Cell Lung CancerNeuroendocrine Carcinoma+1 more
Vyriad, Inc. 33
Testing effectiveness (Phase 2)Ended earlyNCT03829501
What this trial is testing

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Who this might be right for
Squamous Cell Carcinoma of Head and NeckNon-small Cell Lung CancerHepatocellular Carcinoma+9 more
Kymab Limited 222
Early research (Phase 1)Study completedNCT00730639
What this trial is testing

Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

Who this might be right for
Metastatic Castration-resistant Prostrate CancerRenal Cell CarcinomaMetastatic Melanoma+1 more
Bristol-Myers Squibb 395
Load More Results